ProCE Banner Activity

The Potential of Antibody‒Drug Conjugates Targeting CEACAM5 in NSCLC

Clinical Thought

An expert discusses the potential role of antibody‒drug conjugates targeting CEACAM5 in advanced nonsquamous NSCLC.

Released: June 30, 2023

Share

Faculty

David Planchard

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Sanofi.

Sanofi

Disclosure

Primary Author

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

David Planchard, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi.